Clevidipine Clinical Trials Review 081408课件.pptVIP

* * * * * Reference Peacock FW, Varon J, Garrison NA, et al. IV clevidipine for hypertension: safety, efficacy and transition to oral therapy. Poster presented at the American College of Emergency Physicians Annual Meeting; October 8-11, 2007; Seattle, WA. * Of the 11 not transitioning to oral therapy within 6 hr of IV termination: 3 were transitioned from clevidipine but with inadequate BP control despite treatment with multiple oral antihypertensive agents 2 had critical medical conditions preventing use of oral agents 1 discontinued clevidipine without need of oral therapy 5 did not reach the 18-h end point for transition eligibility References Peacock FW, Varon J, Garrison NA, et al. IV clevidipine for hypertension: safety, efficacy and transition to oral therapy. Poster presented at the American College of Emergency Physicians Annual Meeting; October 8-11, 2007; Seattle, WA. Data on file, The Medicines Company. * * * References Peacock FW et al. IV clevidipine for hypertension: safety, efficacy and transition to oral therapy. Poster presented at the American College of Emergency Physicians Annual Meeting; October 8-11, 2007; Seattle, WA. Data on file, The Medicines Company. * * * * * For each end-point, patients are excluded from the denominator if the last follow-up visit was before 30 days postrandomization and no associated end-point was reported. * For each end-point, patients are excluded from the denominator if the last follow-up visit was before 30 days postrandomization and no associated end-point was reported. * For each end-point, patients are excluded from the denominator if the last follow-up visit was before 30 days postrandomization and no associated end-point was reported. * For each end-point, patients are excluded from the denominator if the last follow-up visit was before 30 days postrandomization and no associated end-point was reported. * * * In the currently approved label for Cleviprex (clevidipine butyrate),